Navigation Links
Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
Date:3/13/2013

SAN DIEGO, March 13, 2013 /PRNewswire/ -- Receptos Inc. announced today that it has entered a Development License and Option Agreement to in-license a humanized anti-interleukin-13 (IL-13) antibody asset from AbbVie (NYSE: ABBV).

The asset, designated RPC4046 by Receptos, has completed a first-in-human Phase I study. Under the agreement, Receptos will conduct a Phase 2 clinical study to demonstrate proof-of-concept in Eosinophilic Esophagitis (EoE), an indication designated as an Orphan Disease by the US FDA. AbbVie holds an exclusive option to enter into a global co-development collaboration for RPC4046 with Receptos following results of the planned Phase 2 study and regulatory discussions with the FDA.

"We are honored that AbbVie has entrusted a promising Phase 2-ready therapeutic candidate to the Receptos development team to pursue proof-of-concept in EoE, an Orphan Disease growing in prevalence for which there are no approved treatment options," said Faheem Hasnain , President and Chief Executive Officer of Receptos. "We believe that AbbVie's exceptional track record in immunology will be a strong asset in this collaboration."

Upon exercise of the co-development option, AbbVie and Receptos would enter into a collaboration agreement in which the parties would equally share costs of the Phase 3 clinical program and future development on a global basis. Receptos would retain a right to co-promote RPC4046 and share equally in profits in the United States. Outside of the US, AbbVie would hold sole commercial rights and Receptos would be eligible for double digit royalties on net sales. Additional indications may be pursued under the collaboration, as the mechanism of action has been shown to have potential in various immunological and allergic disorders.

Should AbbVie decline to exercise its co-development option for RPC4046, Receptos would obtain a
'/>"/>

SOURCE Receptos Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals
2. Graham Cooper Appointed Chief Financial Officer of Receptos
3. Receptos to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference
4. Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
5. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
6. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
7. uniQure Licenses RNA Interference Technology to Advance Huntingtons Disease Program
8. Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
9. West Health Institute licenses Kinect-based physical therapy technology to Reflexion Health; West Health Investment Fund makes $4.25 million investment
10. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
11. NTT DATA Licenses DATATRAK ONE™ for China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... LAS VEGAS , Jan. 23, 2015 Cord Blood ... CBAI ) ("CBAI" or the "Company")  filed a Preliminary Proxy ... ( www.sec.gov ) today, and provides an update for shareholders ... authorized shares is requested. Dear Shareholders, ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... organiser UBM Live today reported that a record 2356 unique ... an increase of 17% over 2009 attendance levels, and announced ... be held from 24-26 August, at the Transamerica Expo Center, ... took place from August 17 to 19 at La Rural ...
... Medizone International, Inc. (OTC Bulletin Board, OTCQB: ... patent application covering recent developments in its variant ... countermeasures. The application, filed under the ... countries, including all major industrialized countries for this ...
Cached Medicine Technology:UBM South America Pharma Events Attract Record Attendance 2Medizone International Files For Additional Bio-Terrorism Countermeasures Patent Protection 2
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... 2015 Angelweddingdress is a famous wedding dress ... customers to follow it on Facebook, Twitter, and Pinterest. The ... gift. Angelweddingdress draws a lottery every week. , Moreover, the ... 28, 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David ... Show to bestow a Juvent Sports Achievement award upon ... McKitrick. The award commemorated and congratulated McKitrick for her ... won her first amateur tournament in 1979 and most ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... primary lung adenocarcinoma is exceedingly rare in the ... certain lung tumors in children and adolescents. While ... lesions exist, little research has been conducted to ... malignancies in adults. Through an assessment of clinical, ...
... 1 Nonsteroidal anti-inflammatory drugs (NSAIDs) prevent colon cancer ... researchers at the University of Pittsburgh Cancer Institute (UPCI) ... findings, reported in the early online version of this ... could lead to new strategies to protect people ...
... new ways to treat aggressive brain cancers, an international ... the lowly daffodil. A new research study published in ... Journal ( http://www.fasebj.org ) offers hope that a ... be a powerful therapeutic against biologically aggressive forms of ...
... such as slipping while walking off a curb, may seem ... death in elderly individuals, according to a new study published ... Care . As the population continues to age, it is ... prepared to deal with this issue, which could significantly impact ...
... a common stomach bacterium, reduced the severity of inflammation of the ... from U-M Medical School scientists. More than half the people ... it is very unusual to find it in the United States. ... to hosting the H. pylori infection, says Peter Higgins, ...
... clear guidelines on childhood stroke after a study, published in ... variations in time lag to diagnosis, investigation and treatment. ... rehabilitation services, after a follow-up study found that 85% of ... limitations. Dr Sten Christerson studied the records ...
Cached Medicine News:Health News:Research explores lung cancer among pediatric cancer patients 2Health News:Pitt study finds NSAIDs cause stem cells to self-destruct, preventing colon cancer 2Health News:Scientists turn a new leaf to discover a compound in daffodils that targets brain cancer 2Health News:For elderly, even short falls can be deadly 2Health News:For elderly, even short falls can be deadly 3Health News:Common stomach bacteria may fight off inflammatory bowel disease caused by Salmonella 2Health News:Common stomach bacteria may fight off inflammatory bowel disease caused by Salmonella 3Health News:Childhood stroke study identifies the contraceptive pill and smoking as risk factors 2Health News:Childhood stroke study identifies the contraceptive pill and smoking as risk factors 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: